Use these forms for easy enrollment. Once completed, you can fax them to 1-888-436-0193 or email them to info@ascendissupport.com. For any questions or comments, please call 1-844-442-7236.

Learn more about the A·S·A·P program
SUPPORT PROGRAMOnce you have decided to prescribe your patient once-weekly SKYTROFA, you will initiate Ascendis Signature Access Program™ (A·S·A·P) enrollment for fast fulfillment.
Your patient’s assigned Nurse Advocate coordinates device training and quick delivery of SKYTROFA cartridges and Auto‑Injector, only available through A·S·A·P enrollment.1
Use these forms for easy enrollment. Once completed, you can fax them to 1-888-436-0193 or email them to info@ascendissupport.com. For any questions or comments, please call 1-844-442-7236.
Learn more about the A·S·A·P program
SUPPORT PROGRAMIMPORTANT SAFETY INFORMATION
INDICATION
SKYTROFA® is a human growth hormone indicated for the treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH).
IMPORTANT SAFETY INFORMATION
You are encouraged to report side effects to FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Ascendis Pharma at 1-844-442-7236.
Please click here for full Prescribing Information for SKYTROFA.